Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Personal breast: customizing agents and biomarkers for optimal adjuvant endocrine therapy.

Bardia A, Stearns V.

Breast Cancer Res Treat. 2010 Apr;120(2):437-9. doi: 10.1007/s10549-010-0787-1. Epub 2010 Feb 17. No abstract available.

PMID:
20162380
2.

Extended adjuvant therapy for breast cancer--how much is enough?

Prowell TM, Stearns V.

J Natl Cancer Inst. 2007 Dec 19;99(24):1825-7. Epub 2007 Dec 11. No abstract available.

PMID:
18073372
3.

Aromatase inhibitors as adjuvant treatment of breast cancer.

Geisler J, L√łnning PE.

Crit Rev Oncol Hematol. 2006 Jan;57(1):53-61. Epub 2005 Dec 7. Review.

PMID:
16337805
4.

Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen.

Pritchard KI.

J Clin Oncol. 2005 Aug 1;23(22):4850-2. Epub 2005 Jul 11. No abstract available.

PMID:
16009956
5.

Current concepts in the endocrine therapy of breast cancer: tamoxifen and aromatase inhibitors.

Singh Ranger G.

J Clin Pharm Ther. 2005 Aug;30(4):313-7. Review. Erratum in: J Clin Pharm Ther. 2005 Oct;30(5):496. Sing Ranger, G [corrected to Singh Ranger, G].

PMID:
15985044
6.

The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.

Winer E.

Clin Adv Hematol Oncol. 2008 Aug;6(8):573-4. Review. No abstract available.

PMID:
18820598
7.

The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.

Mouridsen HT, Robert NJ.

Eur J Cancer. 2005 Aug;41(12):1678-89. Epub 2004 Nov 25. Review.

PMID:
16098456
8.
9.

Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group.

Hudis CA, Dang CT.

Breast Dis. 2004;21:3-13. Review. No abstract available.

PMID:
15687717
10.

Advances in adjuvant hormonal therapy for postmenopausal women.

Strasser-Weippl K, Goss PE.

J Clin Oncol. 2005 Mar 10;23(8):1751-9. Review. No abstract available.

PMID:
15755983
11.

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

Buzdar A, Chlebowski R, Cuzick J, Duffy S, Forbes J, Jonat W, Ravdin P.

Curr Med Res Opin. 2006 Aug;22(8):1575-85. Review.

PMID:
16870082
12.

[Adjuvant antihormonal therapy for postmenopausal women with primary operable breast cancer].

Tuxen MK, Nielsen DL, Lindberg H, Kamby C.

Ugeskr Laeger. 2007 Jan 22;169(4):297-9. Review. Danish.

PMID:
17274922
13.

Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.

Cunnick G, Mokbel K.

Int J Fertil Womens Med. 2005 Sep-Oct;50(5 Pt 1):197-8.

PMID:
16468468
14.

Is long-term adjuvant treatment of breast cancer with anastrozole indicated?

Doggrell SA.

Expert Opin Pharmacother. 2008 Jun;9(9):1619-22. doi: 10.1517/14656566.9.9.1619 .

PMID:
18518790
15.

[Neoadjuvant antihormonal treatment of women with breast cancer].

Tuxen MK, Kamby C, Nielsen DL.

Ugeskr Laeger. 2007 Sep 10;169(37):3077-81. Review. Danish.

PMID:
17877952
16.

The adjuvant endocrine treatment revolution: focus on anastrozole.

Jakesz R.

Expert Opin Drug Metab Toxicol. 2006 Apr;2(2):301-12. Review.

PMID:
16866615
17.

The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.

Monnier AM.

Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.

PMID:
17492927
18.

Aromatase inhibitors in breast cancer: current and evolving roles.

Hill J, Moore H.

Cleve Clin J Med. 2002 Jul;69(7):561-7. Review.

PMID:
12109640
20.

Aromatase inhibitors and breast cancer.

Miller WR.

Minerva Endocrinol. 2006 Mar;31(1):27-46. Review.

PMID:
16498362

Supplemental Content

Support Center